Answers are grounded in this paper and cite their sources.
This is the first phase 3 trial of a trastuzumab biosimilar to report long-term survival data similar to originator trastuzumab in patients with MBC. The comparable long-term OS between the trastuzumab-dkst and originator trastuzumab groups further supports the similarity of trastuzumab-dkst with originator trastuzumab and establishes trastuzumab-dkst as a safe and effective treatment option for patients with HER2-positive MBC. ClinicalTrials.gov NCT02472964; 6/16/2015.
No takes yet. Share an insight, caveat, or question.
Rugo et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: